Original Title: Abemaciclib, palbociclib y ribociclib en cáncer de mama

Authors' recommendations: CONCLUSIONS Moderate-quality evidence suggests that adding abemaciclib, palbociclib or ribociclib to endocrine therapy for the treatment of women with metastatic breast cancer who are positive for hormone receptors and no human epidermal growth factor overexpression, did not show an improvement in overall survival during the follow-up periods of assessed studies. Their use did increase progression-free survival and overall response rate and would lead to an increase in the incidence of severe adverse effects such as neutropenia and in the percentage of patients who had to discontinue treatment due to the resulting toxicity. The clinical practice guidelines mention them as a therapeutic alternative, mainly for postmenopausal women with metastatic breast cancer. Palbociclib and ribociclib are currently covered by United States private health sponsors. The public health sponsor from Canada and United Kingdom, only consider covering them after a price-reduction agreement. Due to cost-effectiveness reasons, their coverage is not considered by the Australian public health system. No cost-effectiveness or budgetary impact studies were found in Latin America. The economic assessments found conclude that retail price of palbociclib and ribociclib in Australia, Canada and the United Kingdom was not considered cost-effective.

Project Status: Completed

Year Published: 2018

URL for published report: https://www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)